{"id":"W2947290320","doi":"10.1634/theoncologist.2019-0027","title":"Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; University of Toronto; University Health Network; Royal Victoria Hospital; University of Alberta; Royal Victoria Regional Health Centre; Juravinski Cancer Centre; Montreal General Hospital; McMaster University; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Pembrolizumab; Medicine; Atezolizumab; Oncology; Lung cancer; Internal medicine; Nivolumab; Bevacizumab; Pemetrexed; Anaplastic lymphoma kinase; Chemotherapy; Ipilimumab; Cancer; Immunotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002837176,0.0006232641,0.003131077,0.001921509,0.0002127167,0.001302546,0.0006079994,0.0008398475,0.005471807],"category_scores_gemma":[0.009630376,0.0002631751,0.004696433,0.002513903,0.000307536,0.001018379,0.0004028142,0.0008345342,0.0002715147],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009737018,"about_ca_system_score_gemma":0.001913788,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001253787,"about_ca_topic_score_gemma":0.004338427,"domain_scores_codex":[0.9977744,0.0009977795,0.0006562042,0.0001781394,0.0003399341,0.00005351652],"domain_scores_gemma":[0.9923882,0.005155069,0.001886649,0.00007028165,0.0004107484,0.00008905352],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003240038,0.00009943458,0.001881803,0.7795986,0.01363775,0.0001191872,0.00008837959,0.0002640621,0.0006106904,0.0002863151,0.002606331,0.1975674],"study_design_scores_gemma":[0.009739188,0.005793636,0.01929126,0.6723531,0.2102796,0.001427168,0.0003463185,0.0004653068,0.001426863,0.001390237,0.07741003,0.00007738439],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002802833,0.9958182,0.00007256409,0.0002127784,0.00009243212,0.0001470609,0.0002112975,0.000007570204,0.0006353197],"genre_scores_gemma":[0.0548135,0.9424403,0.0006017394,0.0009558661,0.0002314645,0.0002923863,0.0003927201,0.000005938487,0.0002660909],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005471807,"threshold_uncertainty_score":0.018305,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02960947122563826,"score_gpt":0.3227680076414282,"score_spread":0.2931585364157899,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}